Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancer
Not Applicable
- Conditions
- unresectable advanced gastric cancer
- Registration Number
- JPRN-C000000080
- Lead Sponsor
- Fourth Department of Internal Medicine, Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria included: active infection; serious complications (severe heart disease, pulmonary fibrosis, interstitial pneumonitis and tendency to bleeding); neuropathy grade 2; edema grade 2 (NCI-CTC); active concomitant malignancy; symptomatic metastases of the central nervous system; history of drug hypersensitivity (including TXT,CDDP,TS-1 or G-CSF); serious diarrhea; pregnant and lactating females; females of childbearing age, unless using effective contraception; and other serious medical conditions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy
- Secondary Outcome Measures
Name Time Method survival(PFS,MST) toxicity